Raised to date
$1.5M
of $2.5M offered across 1 Form D filing
PIPr Therapeutics, Inc. (PIPr Tx) is a preclinical-stage biotechnology company based in Durham, North Carolina. The company describes its work as pioneering precision metalloprotease inhibitors. It is led by CEO and co-founder Heather Madsen, a pharmaceutical research executive and Hatteras Venture Partners partner, and its public website is still a pre-launch placeholder with no disclosed pipeline or lead candidates.
The company positions its approach as precision inhibition of metalloproteases - selective targeting of individual enzymes in a protease family whose earlier broad inhibitors were limited by off-target activity. No further differentiation has been disclosed publicly.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Nov 12, 2025 | Equity | $1.5M/ $2.5M | Form D |
Preclinical drug discovery
The company's stated scientific focus: preclinical therapeutic programs built on precise inhibition of metalloprotease targets. No named drug candidates, modalities, or indications have been disclosed publicly.